Literature DB >> 15591896

Vaso-occlusion in children with sickle cell disease: clinical characteristics and biologic correlates.

Carlton Dampier1, B N Yamaja Setty, Barry Eggleston, Darcy Brodecki, Patricia O'neal, Marie Stuart.   

Abstract

Vaso-occlusive pain is a frequent manifestation of sickle cell disease, but most clinical studies have documented only those pain episodes for which patients seek acute care or require hospitalization. Based on limited previous studies, the authors suggest that pain episodes managed at home are more frequent then those resulting in acute care management but likely share a common pathophysiology. The authors determined the characteristics of vaso-occlusive pain managed at home in 30 subjects (ages 6-19 years) using a self-report diary daily for 6 months. A total of 175 pain episodes were reported in 4,885 days, with 51% lasting 1 day or less. Severe pain, rated as 7 to 10 on a 10-point scale, was reported on 12% of pain days, but most pain was of mild to moderate intensity. A combination of baseline hematologic parameters and biomarkers assessing erythrocyte/endothelial cell adhesion, including hematocrit, fetal hemoglobin, and adhesion ratio, were statistically significant predictors of pain frequency in statistical analyses. Given the overlap in clinical features and predictive hematologic parameters of home-managed and acute care-managed pain, both likely represent a continuum of frequency and severity rather than distinct clinical entities. The higher frequency of these home-managed episodes suggests their potential utility as additional outcome measures in studies of vaso-occlusive pain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591896

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  21 in total

1.  Autonomic reactivity and clinical severity in children with sickle cell disease.

Authors:  Sarah R Pearson; Abbey Alkon; Marsha Treadwell; Brian Wolff; Keith Quirolo; W Thomas Boyce
Journal:  Clin Auton Res       Date:  2005-12       Impact factor: 4.435

2.  Pain site frequency and location in sickle cell disease: the PiSCES project.

Authors:  Donna K McClish; Wally R Smith; Bassam A Dahman; James L Levenson; John D Roberts; Lynne T Penberthy; Imoigele P Aisiku; Susan D Roseff; Viktor E Bovbjerg
Journal:  Pain       Date:  2009-07-23       Impact factor: 6.961

3.  Pain characteristics and age-related pain trajectories in infants and young children with sickle cell disease.

Authors:  Carlton Dampier; Beth Ely; Darcy Brodecki; Camille Coleman; Leela Aertker; Jocelyn Andrel Sendecki; Benjamin Leiby; Karen Kesler; Terry Hyslop; Marie Stuart
Journal:  Pediatr Blood Cancer       Date:  2013-09-24       Impact factor: 3.167

4.  The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Authors:  Wally R Smith; Samir K Ballas; William F McCarthy; Robert L Bauserman; Paul S Swerdlow; Martin H Steinberg; Myron A Waclawiw
Journal:  Pain Med       Date:  2011-04-11       Impact factor: 3.750

5.  Relationship of Omega-3 fatty acids DHA and EPA with the inflammatory biomarker hs-CRP in children with sickle cell anemia.

Authors:  B N Yamaja Setty; Suhita Gayen Betal; Robin E Miller; Dawn S Brown; Maureen Meier; Michele Cahill; Norma B Lerner; Nataly Apollonsky; Marie J Stuart
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2019-05-10       Impact factor: 4.006

6.  Remote monitoring of pain and symptoms using wireless technology in children and adolescents with sickle cell disease.

Authors:  Eufemia Jacob; Joana Duran; Jennifer Stinson; Mary Ann Lewis; Lonnie Zeltzer
Journal:  J Am Assoc Nurse Pract       Date:  2012-07-12       Impact factor: 1.165

7.  A biopsychosocial-spiritual model of chronic pain in adults with sickle cell disease.

Authors:  Lou Ella V Taylor; Nancy A Stotts; Janice Humphreys; Marsha J Treadwell; Christine Miaskowski
Journal:  Pain Manag Nurs       Date:  2011-12-14       Impact factor: 1.929

8.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

9.  Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment.

Authors:  Melissa J Frei-Jones; Amy L Baxter; Zora R Rogers; George R Buchanan
Journal:  J Pediatr       Date:  2007-10-24       Impact factor: 4.406

10.  Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events.

Authors:  Amanda M Brandow; David C Brousseau; Julie A Panepinto
Journal:  Br J Haematol       Date:  2008-12-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.